International Center for Diarrheal Disease Research
Also known as: Assistant Scientist | Assistant Scientist, Infectious Diseases Division, icddr,b | Centre for Vaccine Sciences, International Centre for Diarrhoeal Disease Research, Bangladesh | Chief Physician and Head, Hospitals, icddr,b | ICCDR,B | ICDDR,B: Centre for Health and Population Research | ICDDR,B: Centre for Health & Population Research | International Center for Diarrheal Disease Research, Bangladesh | International Center for Diarrhoeal Disease Research, Bangladesh | International Centre for Diarrhoeal Disease Research b | International Centre for Diarrhoeal Disease Research, Bangladesh | International Centre for Diarrhoeal Disease Research, Bangladesh, Centre for Child and Adolescent Health | International Centre for Diarrhoel Disease Research, Bangladesh | International Centre for Diiarrhoeal Disease Research, Bangladesh | Research Fellow, Nutrition & Clinical Services Division, icddr,b | Research Investigator,NCSD, icddr,b | Research Investigator, Nutrition and Clinical Services Division, icddr,b | Senior Director, Nutrition & Clinical Services Division, icddr,b | The International Centre for Diarrhoeal Disease Research, Bangladesh
Highest phase reached
Phase 4
First clinical trial
Jul 1, 1993Last known activity
Dec 8, 2025
Timeline
1960s
- Jan 1, 1960
International Center for Diarrheal Disease Research— Founded
Drugs by trial phase (141 distinct, 171 trials)
Phase 4 (28 own, 0 via acquisition)
- iron
- mifepristone
- DTaP, inactivated poliovirus, haemophilus influenzae b conjugate, hepatitis b vaccine
- miltefosine
- hepatitis b vaccine (recombinant)
- primaquine
- inactivated japanese encephalitis vaccine
- inactivated poliovirus type 2 vaccine
- hepatitis e vaccine
- inactivated influenza vaccine
- live attenuated chimeric japanese encephalitis vaccine
- live oral poliovirus type 1, 2 and 3
- measles-rubella vaccine
- chloroquine
- misoprostol
- +13 more
Phase 3 (35 own, 0 via acquisition)
- vitamin d3
- pancrelipase
- egg
- soybean oil
- ursodeoxycholic acid
- human papillomavirus quadrivalent (types 6, 11, 16 and 18) vaccine, recombinant
- cholera vaccine
- oseltamivir
- caffeine
- epinephrine
- typhoid vi polysaccharide vaccine
- whole wheat allergenic extract
- yellow fever vaccine 17d strain
- ciprofloxacin
- amphotericin b
- +20 more
Phase 2 (37 own, 0 via acquisition)
Phase 1 (10 own, 0 via acquisition)
Indications
Studied for
- Anemia
- Anemia, Iron-Deficiency
- Birth Weight
- Bronchiolitis
- Cachexia
- Campylobacter Infections
- Child Nutrition Disorders
- Cholera
- Communicable Diseases
- Death
- Dengue
- Diarrhea
- Dysentery, Bacillary
- Encephalitis
- Encephalitis, Japanese
- Fever
- Foot-and-Mouth Disease
- Gastroenteritis
- Growth Disorders
- Guillain-Barre Syndrome
- Hand, Foot and Mouth Disease
- Hepatitis
- Hepatitis A
- Hepatitis B
- Hepatitis E
- Infections
- Influenza, Human
- Intestinal Diseases
- Kwashiorkor
- Leishmaniasis
- Leishmaniasis, Visceral
- Malaria
- Malaria, Falciparum
- Malnutrition
- Maternal Death
- Measles
- Mouth Diseases
- Neonatal Sepsis
- Night Blindness
- Perinatal Death
- Pneumonia
- Poliomyelitis
- Pregnancy Complications, Infectious
- Puerperal Infection
- Respiratory Tract Infections
- Rotavirus Infections
- Rubella
- Rubella Syndrome, Congenital
- Sepsis
- Severe Acute Malnutrition
- Sprue, Tropical
- Syndrome
- Thinness
- Toxemia
- Tuberculosis
- Tuberculosis, Pulmonary
- Typhoid Fever
- Uterine Cervical Neoplasms
- Vibrio Infections
- Virus Diseases
- Vitamin A Deficiency
- Wasting Syndrome
Recent trials (50)
- NCT07010822OfficialPhase 3Dec 8, 2025
- NCT07207434CollaboratorPhase 2Aug 30, 2025
- NCT07045493Lead sponsorPhase 2Jul 10, 2025
- NCT06723392CollaboratorPhase 1Jun 30, 2025
- NCT06855108CollaboratorPhase 3Jun 30, 2025
- NCT06817031Lead sponsorPhase 2Apr 30, 2025
- NCT06757283Lead sponsorPhase 3Apr 1, 2025
- NCT06815835Lead sponsorPhase 3Apr 1, 2025
- NCT06748612Lead sponsorPhase 4Jan 28, 2025
- NCT06114810Lead sponsorPhase 4Nov 30, 2023
- NCT06114810Overall official - principal investigatorPhase 4Nov 30, 2023
- NCT06251739OfficialEarly Phase 1Oct 30, 2023
- NCT06251739Lead sponsorEarly Phase 1Oct 30, 2023
- NCT05771779Lead sponsorPhase 3Oct 14, 2023
- NCT05771779Overall official - principal investigatorPhase 3Oct 14, 2023
Details
- Founded
- Dhaka, BD Jan 1, 1960
- Last known activity
- Dec 8, 2025